1. Search Result
Search Result
Results for "

neurodegenerative related diseases

" in MedChemExpress (MCE) Product Catalog:

120

Inhibitors & Agonists

9

Screening-Bibliotheken

3

Fluorescent Dyes

2

Biochemical Assay Reagents

2

Peptides

2

Inhibitory Antibodies

25

Natural
Products

7

Isotope-Labeled Compounds

1

Oligonucleotides

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-113324
    NADPH
    Maximum Cited Publications
    18 Publications Verification

    Endogenous Metabolite Cancer
    NADPH is a coenzyme of glutathione reductase (GR), thioredoxin reductase (TrxR) and NADPH oxidase (NOX), and participates in redox reactions as a hydrogen donor. NADPH has the characteristic of selectively participating in the regulation of cellular redox homeostasis. NADPH exerts antioxidant activity and resists reactive oxygen species (ROS) damage by providing reducing equivalents for the regeneration of glutathione (GSH) and thioredoxin (Trx); at the same time, it acts as a substrate of NOX to generate superoxide anions, mediating oxidative stress and immune response. NADPH participates in maintaining the intracellular reducing environment, biosynthesis and regulating gene expression (such as the Nrf2 pathway), and is mainly used in the study of oxidative stress-related diseases (such as cardiovascular diseases, neurodegenerative diseases, cancer) and immune regulation mechanisms .
    NADPH
  • HY-111914A
    Ferroheme
    1 Publications Verification

    NO Synthase Fatty Acid Synthase (FASN) Cardiovascular Disease
    Ferroheme is the ferrous form of heme in hemoglobin, reversibly binding oxygen as an oxygen carrier. Its free form induces oxidative stress and ferroptosis by releasing iron ions, which catalyze reactive oxygen species generation via Fenton reactions, leading to lipid peroxidation and cell death. This mechanism is critical in pathological contexts like intracerebral hemorrhage and neurodegenerative diseases, making it a target for studying iron-overload disorders and ferroptosis-related pathologies[1][2][3].
    Ferroheme
  • HY-B0504S
    Creatinine-d3
    5 Publications Verification

    NSC13123-d3

    Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor Metabolic Disease Cancer
    Creatinine-d3 is a deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine-d3
  • HY-103242

    Amyloid-β Neurological Disease
    CRANAD-2 is a specific near-infrared (NIR) fluorescent probe for detecting plaques (unbound to Aβ: Ex=640 nm; Em=805 nm; after binding: Em=715 nm). CRANAD-2 penetrates the blood-brain barrier and has high affinity for Aβ aggregates, with a Kd value of 38 nM. CRANAD-2 is applicable to research related to Alzheimer's disease and neurodegenerative diseases .
    CRANAD-2
  • HY-B0762
    Acetyl-L-carnitine hydrochloride
    2 Publications Verification

    O-Acetyl-L-carnitine hydrochloride; ALCAR hydrochloride

    Caspase Apoptosis Neurological Disease
    Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) hydrochloride is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine hydrochloride selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine hydrochloride can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine hydrochloride exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine hydrochloride is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
    Acetyl-L-carnitine hydrochloride
  • HY-B0504
    Creatinine
    5+ Cited Publications

    NSC13123

    Endogenous Metabolite GABA Receptor iGluR Infection Neurological Disease Metabolic Disease Cancer
    Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine
  • HY-125623
    MitoPerOx
    3 Publications Verification

    Fluorescent Dye Others
    MitoPerOx is a mitochondrial-targeted, lipid peroxidation-indicating fluorescent probe with BODIPY581/591 fluorophores. The triphenylphosphine cation (TPP+) of MitoPerOx can be selectively enriched in mitochondria (depending on membrane potential) and can be used to detect lipid peroxidation in the inner mitochondrial membrane. Under the action of lipid peroxides, the BODIPY581/591 fluorophores of MitoPerOx shift their emission wavelength from 590 nm (reduced state) to 520 nm (oxidized state), and ratiometric detection can be performed at an excitation wavelength of 488 nm. MitoPerOx can specifically monitor the peroxidation of mitochondrial phospholipids (especially cardiolipin) and is used in the study of oxidative stress-related diseases (such as aging, neurodegenerative diseases, and mitochondrial dysfunction)[1][2].
    MitoPerOx
  • HY-128700
    Nicotinic acid mononucleotide
    1 Publications Verification

    Endogenous Metabolite Sirtuin Neurological Disease Inflammation/Immunology Cancer
    Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD + biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD + levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD + levels. Nicotinic acid mononucleotide is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease .
    Nicotinic acid mononucleotide
  • HY-113218
    Acetyl-L-carnitine
    2 Publications Verification

    O-Acetyl-L-carnitine; ALCAR

    Caspase Apoptosis Neurological Disease
    Acetyl-L-carnitine (O-Acetyl-L-carnitine; ALCAR) is an orally active mitochondrial energy metabolism regulator and neuroprotectant that can penetrate the blood-brain barrier. Acetyl-L-carnitine selectively enters cells and the brain through the organic cation transporter OCTN2. Acetyl-L-carnitine can participate in fatty acid β-oxidation, promote acetylcholine synthesis, regulate mitochondrial function and inhibit oxidative stress as an acetyl donor. Acetyl-L-carnitine exerts its activity by enhancing energy metabolism, protecting neurons and improving synaptic plasticity. Acetyl-L-carnitine is mainly used in the study of neurodegenerative diseases and metabolic disorder-related diseases such as neonatal hypoxic-ischemic brain damage, Alzheimer's disease, and depression .
    Acetyl-L-carnitine
  • HY-P991049

    ATM-001

    TNF Receptor Metabolic Disease Inflammation/Immunology
    Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis .
    Atrosimab
  • HY-B0504S2

    NSC13123-d5

    Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor Metabolic Disease
    Creatinine-d5 is the deuterium labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine-d5
  • HY-D0961

    Fluorescent Dye Wnt β-catenin Neurological Disease Inflammation/Immunology Cancer
    Gallocyanine chloride is a synthetic blue dyestuff that can be used as a potential agent for the research of Alzheimer's disease and related neurodegenerative tauopathies. Gallocyanine chloride inhibits DKK1/LRP6 interaction (IC50=6.38 μM), activates Wnt signaling pathway, and causes β-catenin accumulation. Gallocyanine chloride exhibits anti-metastasis, anti-inflammatory and anti-fibrosis activities. Gallocyanine chloride can be used as a fluorescent probe for detection of superoxide anion radicals .
    Gallocyanine chloride
  • HY-N1100

    (-)-Vasicinone

    Others Neurological Disease
    Vasicinone is a quinazoline alkaloid isolated from the Adhatoda vasica. Vasicinone is a potential agent for Parkinson's disease and possibly other oxidative stress-related neurodegenerative disorders .
    Vasicinone
  • HY-160236

    Drug Metabolite Neurological Disease
    3-(3-Sulfooxyphenyl) propanoic acid is a metabolite of Echinacoside (HY-N0020). It promotes neural, psychological and brain health, enhances the proliferation, function and activity of brain cells, and facilitates extinction learning. 3-(3-Sulfooxyphenyl) propanoic acid can be used in research related to anxiety disorders, post-traumatic stress disorder, extinction learning deficits, autism, as well as neurodegenerative diseases including Parkinson's disease and Alzheimer's disease .
    3-(3-Sulfooxyphenyl)propanoic acid
  • HY-N8220

    Flidersiachromone

    Glycosidase Neurological Disease Cancer
    2-(2-Phenylethyl) chromone (Flidersiachromone) is a chromone derivative and antioxidant. 2-(2-Phenylethyl) chromone scavenges ABTS· + free radicals, and its derivatives exhibit diverse activities including anti-inflammatory, neuroprotective, anti-tumor, and α-glucosidase inhibitory effects. 2-(2-Phenylethyl) chromone is applicable to experimental research in fields such as inflammation-related diseases, tumors, and neurodegenerative diseases .
    2-(2-Phenylethyl)chromone
  • HY-145232
    PhosTAC7
    4 Publications Verification

    OGTAC-3

    PhosTACs Phosphatase Tau Protein Neurological Disease Cancer
    PhosTAC7 is a heterobifunctional molecule named as a Phosphorylation Targeting Chimera (PhosTAC). PhosTAC7 can dephosphorylate the PDCD4 protein, FOXO3a protein, and tau protein by recruiting serine/threonine protein phosphatase 2A (PP2A). PhosTAC7 offers the advantage of selectively modulating the phosphorylation state of individual target proteins, making it a promising tool for research in cancer and tau protein-related neurodegenerative diseases (Alzheimer's disease) .
    PhosTAC7
  • HY-137441
    Icapamespib
    1 Publications Verification

    PU-HZ151

    HSP Neurological Disease Cancer
    Icapamespib (PU-HZ151; PU-AD) is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
    Icapamespib
  • HY-114869
    DPQ
    3 Publications Verification

    PARP Neurological Disease Cancer
    DPQ is a selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD +/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases .
    DPQ
  • HY-115733
    Cathepsin L-IN-2
    1 Publications Verification

    (Rac)-Z-Phe-Phe-FMK

    Cathepsin Cancer
    Cathepsin L-IN-2 ((Rac)-Z-Phe-Phe-FMK) is an isomer of the Cathepsin L inhibitor Z-Phe-Phe-FMK (HY-141867), with an IC50 of 15 μM for cathepsin L. Z-Phe-Phe-FMK irreversibly blocks the proteolytic function of cathepsins by covalently binding to the cysteine residues in the active center of the enzyme. Cathepsin L-IN-2 and Z-Phe-Phe-FMK can be used to study neurodegenerative diseases (such as GRN-related frontotemporal dementia) and cancer invasion and metastasis.
    Cathepsin L-IN-2
  • HY-DY1073

    Fluorescent Dye Others
    MitoPerOx (solution) is a mitochondrial-targeted, lipid peroxidation-indicating fluorescent probe with BODIPY581/591 fluorophores. The triphenylphosphine cation (TPP+) of MitoPerOx can be selectively enriched in mitochondria (depending on membrane potential) and can be used to detect lipid peroxidation in the inner mitochondrial membrane. Under the action of lipid peroxides, the BODIPY581/591 fluorophores of MitoPerOx shift their emission wavelength from 590 nm (reduced state) to 520 nm (oxidized state) , and ratiometric detection can be performed at an excitation wavelength of 488 nm. MitoPerOx can specifically monitor the peroxidation of mitochondrial phospholipids (especially cardiolipin) and is used in the study of oxidative stress-related diseases (such as aging, neurodegenerative diseases, and mitochondrial dysfunction) .
    Solvent and concentration: DMSO: 2 mM
    MitoPerOx (solution)
  • HY-125931

    DM232

    iGluR Neurological Disease Inflammation/Immunology
    Unifiram (DM232) is a AMPA receptor activator and cognitive enhancer. Unifiram activates the AMPA-mediated neurotransmission system. Unifiram reverses NBQX-induced amnesia in the passive avoidance test in mice. Unifiram reverses the antagonistic effect of kynurenic acid on NMDA-mediated [ 3H]NA release in rat hippocampal slices. Unifiram enhances excitatory synaptic transmission in the rat hippocampus in vitro. Unifiram can be used in studies related to amnesia and cognitive dysfunction, including age-related memory decline, neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, multiple sclerosis, schizophrenia, and attention deficit hyperactivity disorder .
    Unifiram
  • HY-P10861A

    Tau Protein Neurological Disease
    RI-AG03 acetate is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 acetate inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 acetate mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 acetate suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 acetate can be used for research on tau-related diseases such as Alzheimer's disease .
    RI-AG03 acetate
  • HY-B0504S1

    NSC13123-13C

    Isotope-Labeled Compounds Endogenous Metabolite iGluR GABA Receptor Metabolic Disease
    Creatinine- 13C is the 13C-labeled Creatinine. Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .
    Creatinine-13C
  • HY-W181102

    Calcineurin Cardiovascular Disease Neurological Disease Inflammation/Immunology
    NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17) .
    NFAT Inhibitor-2
  • HY-N7607

    Reactive Oxygen Species (ROS) Cardiovascular Disease
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside is a flavonoid glycoside with antioxidant activity and free radical scavenging activity. Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside can scavenge free radicals such as ABTS+ and can be used in the study of antioxidant-related diseases (such as cardiovascular diseases and neurodegenerative diseases) .
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside
  • HY-N11229

    Caffeic acid butyl ester

    Drug Derivative Neurological Disease
    Butyl caffeate (Caffeic acid butyl ester) is a caffeic acid derivative with antioxidant activity and lipophilicity (DPPH IC50 = 14.1 μM). Butyl caffeate protects neuronal PC12 cells against oxidative stress. Butyl caffeate can be used for oxidative stress related and neurodegenerative diseases research .
    Butyl caffeate
  • HY-113033

    Others Biochemical Assay Reagents Neurological Disease Metabolic Disease Inflammation/Immunology
    Pentosidine is a fluorescent advanced glycation end product (AGE) and cross-linker. Pentosidine is a fluorescent cross-linked structure formed by lysine and arginine in sugar oxidation reactions, and it is commonly found in collagen, skin, bone, lens and plasma proteins . Pentosidine is used in research related to type 1 diabetes, brown cataracts, rheumatoid arthritis, atherosclerosis and neurodegenerative diseases .
    Pentosidine
  • HY-14562

    mAChR Amyloid-β Neurological Disease Inflammation/Immunology
    TBPB (tert-butyl peroxybenzoate) is a highly selective, blood-brain-permeable M1 mAChR allosteric agonist (EC50=289 nM) with anti-schizophrenia and anti-inflammatory activities. TBPB can enhance the sensitivity of M1 receptors to acetylcholine, activate downstream signaling pathways, and inhibit the release of pro-inflammatory cytokines (TNF-α, IL-6). TBPB can regulate the processing of amyloid and can be used in the study of neurodegenerative diseases (such as Alzheimer's disease) and inflammation-related diseases (such as sepsis) .
    TBPB
  • HY-106432A

    SB-202026 hydrochloride; Memric hydrochloride

    mAChR Dopamine Receptor Neurological Disease
    Sabcomeline (SB-202026; Memric) hydrochloride is a muscarinic receptor agonist capable of crossing the blood-brain barrier. Sabcomeline hydrochloride exhibits affinity for all hM1 to hM5 subtypes (pKi=6.72-7.23), and shows near-full agonism at the hM3 receptor, inducing extracellular acidification. Sabcomeline hydrochloride alters the binding kinetics of dopamine D2 receptors through neural network regulation. Sabcomeline hydrochloride also causes minimal cardiovascular changes, effectively reverses spatial memory deficits in rodents and induces conditioned taste aversion. Sabcomeline hydrochloride is an important tool compound in studies of Alzheimer's disease and related neurodegenerative diseases .
    Sabcomeline hydrochloride
  • HY-142026

    (+)-Vitisin A

    Caspase ERK NF-κB Influenza Virus PAK LDLR PPAR PCSK9 Androgen Receptor Keap1-Nrf2 Monoamine Oxidase Cholinesterase (ChE) IKK Wnt β-catenin Reactive Oxygen Species (ROS) Apoptosis Cuproptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Vitisin A ((+)-Vitisin A) is an orally active natural product with multiple pharmacological activities including anti-inflammatory, anti-tumor, anti-oxidant, anti-pathogenic microorganism, hypoglycemic and lipid-regulating, anti-osteoporotic, neuroprotective and cardiovascular protective effects. Vitisin A exhibits inhibitory effects on human AChE and MAO-B with IC50 values of 1.29 µM and 4.94 µM, respectively. Vitisin A inhibits the ERK, MAPK, NF-κB, STAT1, HMGCR and TRAF6 pathways, downregulates the related phosphorylation and protein expression, while activates the Nrf2/HO-1 pathway and upregulates p21 expression. Vitisin A induces tumor cell apoptosis and cell cycle arrest, inhibits adipogenesis and lipid accumulation, while alleviates oxidative stress, suppresses inflammatory responses, blocks hepatic fibrosis, Cuproptosis and cholesterol synthesis, and increases the expression levels of central BDNF and TrkB. Vitisin A can be used in the research of tumors, infectious diseases, metabolic diseases, bone and joint diseases, liver diseases, skin injuries, as well as neurodegenerative and cognitive dysfunction-related diseases .
    Vitisin A
  • HY-147108

    Mitochondrial Metabolism Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Mitochondria degrader-1 (example 5) is a potent mitochondria degrader. Mitochondria degrader-1 induces the degradation of the injured mitochondria by the autophagy mechanism. Mitochondria degrader-1 can be used for the research of neurodegenerative disease, cancer, inflammatory disease, age-related disease, metabolic disease, mitochondrial disease or Down's disease .
    Mitochondria degrader-1
  • HY-W074537

    Phosphodiesterase (PDE) Neurological Disease
    P7-2104 is a blood-brain barrier-permeable, selective PDE7A inhibitor with an IC50 of 31 nM. P7-2104 shows selectivity for hERG channels and most CYP450 subtypes. P7-2104 can be used for PDE7-targeted PET neuroimaging studies and research related to neurodegenerative diseases, when labeled with 11C or 18F .
    P7-2104
  • HY-137441A
    Icapamespib hydrochloride
    1 Publications Verification

    PU-HZ151 hydrochloride

    HSP Neurological Disease Cancer
    Icapamespib (PU-HZ151; PU-AD) hydrochloride is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib hydrochloride can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib hydrochloride can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib hydrochloride can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer .
    Icapamespib hydrochloride
  • HY-148629

    JNK Neurological Disease
    GDC-0134 (RG6000) is a modulator targeting dual leucine zipper kinase (DLK) that can cross the blood-brain barrier. By inhibiting the kinase activity of DLK, GDC-0134 blocks the activation of the downstream JNK signaling pathway, suppresses DLK-dependent retrograde signal transduction of axon-to-soma degeneration, and exerts neuroprotective activity. GDC-0134 reduces TDP-43 protein aggregation and decreases the degree of neuromuscular junction denervation in motor neurons. GDC-0134 can be used in the research of amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other DLK-related neurodegenerative diseases .
    GDC-0134
  • HY-124609

    AMPK Acetyl-CoA Carboxylase Neurological Disease
    CAD031 is an orally active AMPK/ACC1 signaling pathway activator and a derivative of the Alzheimer's disease (AD) targeted agent J147 (HY-13779) (more active than J147 in human neural stem cell assays). CAD031 can cross the blood-brain barrier, activate AMPK and inhibit ACC1, thereby increasing ac-CoA levels, improving mitochondrial function and reducing free fatty acid synthesis. CAD031 has neuroprotective, neurogenesis-promoting and memory-improving activities and can be used in the study of Alzheimer's disease and aging-related neurodegenerative diseases. CAD031 effectively enhances the memory of mice, improves dendritic structure, and stimulates cell division in the germinal zone of the brain of elderly mice .
    CAD031
  • HY-W002438

    Biochemical Assay Reagents Endogenous Metabolite OAT Ferroptosis Neurological Disease Metabolic Disease
    6-Hydroxyindole is an orally active, endogenous long-acting OATP1B1 inhibitor. 6-Hydroxyindole does not alter the cell surface expression or subcellular localization of OATP1B1. 6-Hydroxyindole protects cells against Ferroptosis. 6-Hydroxyindole possesses intrinsic radical-trapping antioxidant activity. 6-Hydroxyindole serves as a component of oxidative hair dyes. 6-Hydroxyindole can be used in research related to renal failure and neurodegenerative diseases .
    6-Hydroxyindole
  • HY-P10861

    Tau Protein Neurological Disease
    RI-AG03 is a proteolytically stable tau aggregation inhibitor that crosses the blood-brain barrier and exhibits oral efficacy. RI-AG03 inhibits tau aggregation and promotes the formation of alternative amorphous aggregates that are non-amyloidogenic. RI-AG03 mediates cellular uptake through direct membrane penetration and macropinocytosis, and its conjugation with cell-penetrating peptide sequences (CPPs) enhances the binding of cells to liposomes. RI-AG03 suppresses aggregation-dependent neurodegenerative and behavioral phenotypes, and extends the lifespan of Drosophila models of tauopathy. RI-AG03 can be used for research on tau-related diseases such as Alzheimer's disease .
    RI-AG03
  • HY-174340

    Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 13 (Compound 1) is a potent nuclear receptor related 1 (Nurr1, NR4A2) agonist with an EC50 value of 0.06 μM. Nurr1 agonist 13 is promising for research of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis .
    Nurr1 agonist 13
  • HY-113155A

    Drug Intermediate Neurological Disease
    17-Hydroxypregnenolone sulfate sodium is a key intermediate in adrenal and gonadal steroidogenesis. 17-Hydroxypregnenolone sulfate sodium acts as a precursor in the biosynthesis of steroid hormones (e.g., glucocorticoids, sex hormones). 17-Hydroxypregnenolone sulfate sodium is promising for research of adrenal function development and neurosteroid-related diseases (e.g., cognitive impairment, neurodegenerative diseases) .
    17-Hydroxypregnenolone sulfate sodium
  • HY-175453

    Molecular Glues Neurological Disease Cancer
    MRT-23227 is a molecular glue degrader that targets cereblon (CRBN). MRT-23227 forms a ternary complex with CRBN and G3BP2, activating the ubiquitin-proteasome system, leading to G3BP2 degradation. MRT-23227 has potential applications in the research of G3BP2-related cancers (such as breast and lung cancer) and neurodegenerative diseases .
    MRT-23227
  • HY-173276

    Toll-like Receptor (TLR) Neurological Disease
    SARM1-IN-4 (Compound 7) is an orally active SARM1 inhibitor. After being orally administered at a dose of 50 mg/kg in a mouse model, it can reduce the level of plasma neurofilament light chain (NfL). SARM1-IN-4 prevents programmed axonal degeneration by inhibiting the NAD+ hydrolase activity of SARM1, and it can be used in research related to neurodegenerative diseases and neurological disorders (such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, and peripheral neuropathies, etc.).
    SARM1-IN-4
  • HY-176540

    Microtubule/Tubulin Neurological Disease
    Microtubule stabilizer-1 (compound 69) is a brain-penetrant microtubule (MT) stabilizer. Microtubule stabilizer-1 increases acetylated α-tubulin (AcTub) levels and prevents the characteristic loss of neuronal MTs that is observed after incubation with Okadaic acid (HY-N6785). Microtubule stabilizer-1 can be used for the study of Alzheimer’s disease (AD) and related neurodegenerative tauopathies .
    Microtubule stabilizer-1
  • HY-147225

    AUTACs Mitophagy Neurological Disease Metabolic Disease Cancer
    TSPO Ligand-Linker Conjugates 1 contains a ligand for translocator protein (TSPO) and a linker, which is used for the synthesis of mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC can bind the TSPO on the outer mitochondrial membrane (OMM) of mitochondria and degrades impaired mitochondria and proteins via mitophagy, and improves mitochondrial activity. TSPO Ligand-Linker Conjugates 1 can be used in mitochondrial dysfunction related research, including neurodegenerative diseases, cancer, and diabetes .
    TSPO Ligand-Linker Conjugates 1
  • HY-W338446

    Tau Protein Neurological Disease
    BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases .
    BF-170
  • HY-114727

    Phosphodiesterase (PDE) Inflammation/Immunology
    PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases .
    PDE7-IN-4
  • HY-128700A

    Endogenous Metabolite Sirtuin Metabolic Disease
    Nicotinic acid mononucleotide triethylamine acts as a SARM1 inhibitor and a NAD + biosynthesis intermediate, with an IC50 value of 93.3 μM against SARM1. Nicotinic acid mononucleotide triethylamine exerts axon-protective effects, delays axonal degeneration, elevates NAD + levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide triethylamine reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD + levels. Nicotinic acid mononucleotide triethylamine is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease .
    Nicotinic acid mononucleotide triethylamine
  • HY-152254

    FAAH Cannabinoid Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The Ki values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC50 value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection .
    CB2R/FAAH modulator-3
  • HY-153560

    Phospholipase Neurological Disease
    Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC50 of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like .
    Lp-PLA2-IN-14
  • HY-153559

    Phospholipase Neurological Disease
    Lp-PLA2-IN-13 (compound 15) is a potent Lp-PLA2 inhibitor. Lp-PLA2-IN-13 has the potential for the research of neurodegenerative related diseases .
    Lp-PLA2-IN-13
  • HY-174329

    Molecular Glues Neurological Disease Cancer
    MRT-5702D is a G3BP2 molecular glue degrader. MRT-5702D forms a CRBN-MRT-5702D-G3BP2 ternary complex to activate the ubiquitin-proteasome system for G3BP2 degradation. MRT-5702D can be used for research of G3BP2-related cancers and neurodegenerative diseases .
    MRT-5702D

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

 

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

 

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: